首页> 外文期刊>Advanced drug delivery reviews >Women and heart disease--physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease.
【24h】

Women and heart disease--physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease.

机译:妇女与心脏病-基因传递和表达的生理调节:可生物还原的聚合物和缺血诱导的基因疗法用于治疗缺血性心脏病。

获取原文
获取原文并翻译 | 示例
           

摘要

Ischemic heart disease (IHD) is the leading cause of death in the United States today. This year over 750,000 women will have a new or recurrent myocardial infarction. Currently, the mainstay of therapy for IHD is revascularization. Increasing evidence, however, suggests that revascularization alone is insufficient for the longer-term management of many patients with IHD. To address these issues, innovative therapies that extend beyond revascularization to protection of the myocyte and preservation of ventricular function are required. The emergence of gene therapy and proteomics offers the potential for innovative prophylactic and treatment strategies for IHD. The goal of our research is to develop therapeutic gene constructs for the treatment of myocardial ischemia that are clinically safe and effective. Toward this end, we describe the development of physiologic regulation of gene delivery and expression using bioreducible polymers and ischemia-inducible gene therapies for the potential treatment of ischemic heart disease in women.
机译:如今,缺血性心脏病(IHD)是导致死亡的主要原因。今年,将有超过750,000名妇女患有新发或复发的心肌梗塞。目前,IHD治疗的主要手段是血运重建。然而,越来越多的证据表明,仅血管重建不足以对许多IHD患者进行长期治疗。为了解决这些问题,需要创新的疗法,其应从血运重建扩展到保护心肌细胞和保持心室功能。基因治疗和蛋白质组学的出现为IHD的创新性预防和治疗策略提供了潜力。我们研究的目标是开发临床上安全有效的用于治疗心肌缺血的治疗性基因构建体。为此,我们描述了使用可生物还原的聚合物和缺血诱导的基因疗法对妇女进行缺血性心脏病的潜在治疗,对基因的传递和表达进行生理调节的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号